Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 306Lymphoma, Non-Hodgkin 227Lymphoma, Large B-Cell, Diffuse 220Lymphoma, Follicular 201Leukemia, Lymphocytic, Chronic, B-Cell 168Lymphoma, B-Cell 147Recurrence 124Burkitt Lymphoma 117Lymphoma, Mantle-Cell 112Leukemia, Myeloid, Acute 106Leukemia 103Hodgkin Disease 102Multiple Myeloma 95Lymphoma, B-Cell, Marginal Zone 87Neoplasms 80Myelodysplastic Syndromes 69Lymphoma, T-Cell, Peripheral 62Hematologic Neoplasms 61Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 58Lymphoma, T-Cell 52Lymphoma, T-Cell, Cutaneous 44Waldenstrom Macroglobulinemia 41Leukemia, Biphenotypic, Acute 35Mycosis Fungoides 31Lymphoproliferative Disorders 30Leukemia, B-Cell 30Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Breast Neoplasms 28Myeloproliferative Disorders 26

Interventions

Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lymphomatoid Papulosis × Lymphoid × Clear all
NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
58 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

NCT06207812 2026-01-26

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

M.D. Anderson Cancer Center

Recruiting
100 enrolled
Lymphoid

Mycosis Fungoides, Lymphomatoid Papulosis

NCT02840747 2025-11-04

Tissue Repository: CTCL Collection Protocol

Columbia University

Recruiting
400 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡